SG11202005772YA - Mhc class i associated peptides for prevention and treatment of multiple flavi virus - Google Patents

Mhc class i associated peptides for prevention and treatment of multiple flavi virus

Info

Publication number
SG11202005772YA
SG11202005772YA SG11202005772YA SG11202005772YA SG11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA
Authority
SG
Singapore
Prior art keywords
prevention
treatment
mhc class
associated peptides
flavi virus
Prior art date
Application number
SG11202005772YA
Inventor
Ramila Philip
Original Assignee
Emergex Vaccines Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holding Ltd filed Critical Emergex Vaccines Holding Ltd
Publication of SG11202005772YA publication Critical patent/SG11202005772YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/18Togaviridae; Flaviviridae
    • C07K14/1816Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202005772YA 2018-01-06 2019-01-04 Mhc class i associated peptides for prevention and treatment of multiple flavi virus SG11202005772YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614375P 2018-01-06 2018-01-06
PCT/GB2019/050024 WO2019135086A1 (en) 2018-01-06 2019-01-04 Mhc class i associated peptides for prevention and treatment of multiple flavi virus

Publications (1)

Publication Number Publication Date
SG11202005772YA true SG11202005772YA (en) 2020-07-29

Family

ID=65234592

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005772YA SG11202005772YA (en) 2018-01-06 2019-01-04 Mhc class i associated peptides for prevention and treatment of multiple flavi virus

Country Status (11)

Country Link
US (3) US11690904B2 (en)
EP (1) EP3735269A1 (en)
JP (1) JP2021509400A (en)
CN (1) CN111565746A (en)
AU (1) AU2019205627B2 (en)
BR (1) BR112020012021A2 (en)
MX (1) MX2020006357A (en)
PH (1) PH12020500579A1 (en)
SG (1) SG11202005772YA (en)
WO (1) WO2019135086A1 (en)
ZA (1) ZA202003770B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019186199A1 (en) * 2018-03-29 2019-10-03 Emergex Vaccines Holding Limited Vaccine compositions
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
CN114980920A (en) 2019-11-18 2022-08-30 詹森生物科技公司 Vaccine based on mutant CALR and JAK2 and uses thereof
TW202144389A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in multiple myeloma and their uses
TW202144388A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in ovarian cancer and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2023069551A1 (en) * 2021-10-20 2023-04-27 The Regents Of The University Of California Multi-epitope mrna sars-cov-2 vaccine for boosting immunity through the activation of cd4 and cd8 t cells as well as b lymphocytes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
WO2005014627A1 (en) * 2003-08-07 2005-02-17 International Centre For Genetic Engineering And Biotechnology Recombinant dengue multi epitope proteins as diagnostic intermediates
EP1793863B1 (en) 2004-10-01 2017-04-12 Midatech Ltd. Nanoparticles comprising antigens and adjuvants capable of stimulating t helper cells
CA2617869C (en) 2005-08-04 2017-02-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
AU2007242572B2 (en) 2006-04-13 2011-11-24 Midatech Limited Nanoparticles containing three various ligands for providing immune responses against infectious agents
US8512991B2 (en) * 2007-08-22 2013-08-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use
CA2802031C (en) * 2010-06-10 2015-05-12 Midatech Limited Peptide-carrying nanoparticles
BR112013032421A2 (en) * 2011-06-29 2017-01-17 Immunotope Inc method for prophylaxis or treatment of a dengue virus infection, method for inducing a cytotoxic t-lymphocyte mediated immune response, dengue virus vaccine, method for preventing a dengue virus disease, and method for inducing an immune response to at least one dengue virus
JP6077544B2 (en) 2011-09-07 2017-02-08 ミダテック リミテッド Nanoparticle-peptide composition
WO2013059403A1 (en) * 2011-10-19 2013-04-25 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of influenza virus infection
WO2015048149A1 (en) * 2013-09-24 2015-04-02 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
WO2015175361A1 (en) * 2014-05-13 2015-11-19 Immunotope, Inc. Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. Tropical disease vaccines
SG11201806340YA (en) 2016-02-17 2018-09-27 Curevac Ag Zika virus vaccine
WO2018218355A1 (en) * 2017-05-30 2018-12-06 Western University Method of diagnosing flavivirus infection
SG11202002044WA (en) 2017-09-21 2020-04-29 Emergex Vaccines Holding Ltd MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus

Also Published As

Publication number Publication date
EP3735269A1 (en) 2020-11-11
US11690904B2 (en) 2023-07-04
JP2021509400A (en) 2021-03-25
US20230346908A1 (en) 2023-11-02
MX2020006357A (en) 2020-08-17
US20240050548A1 (en) 2024-02-15
WO2019135086A1 (en) 2019-07-11
PH12020500579A1 (en) 2021-05-17
BR112020012021A2 (en) 2020-12-22
CN111565746A (en) 2020-08-21
AU2019205627B2 (en) 2024-05-09
AU2019205627A1 (en) 2020-06-11
US20210361760A1 (en) 2021-11-25
ZA202003770B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
SG11202005772YA (en) Mhc class i associated peptides for prevention and treatment of multiple flavi virus
IL277648A (en) Therapeutic microbiota for the treatment and/or prevention of food allergy
HK1248546A1 (en) Combination of wt1 antigen peptide and immunomodulator
IL281277A (en) Compositions and methods for the treatment of viral infections
ZA201905851B (en) Peptides and methods for the treatment of diabetes
IL263368A (en) Prevention and treatment of viral infections
HK1251616A1 (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
FI3773689T3 (en) Antigenic peptides for prevention and treatment of cancer
SG11202002044WA (en) MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
IL284029B1 (en) Peptides for treatment and prevention of diabetes and associated disorders
IL282904A (en) Therapeutic microbiota for the treatment and/or prevention of dysbiosis
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
HUE049890T2 (en) Recombinant lumpy skin disease virus knock-out mutant and uses thereof
DK3810128T3 (en) COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTEIN AGGREGATION DISEASES
EP3617222A4 (en) Peptide for inducing regeneration of tissue, and use thereof
IL280450A (en) Cdca1-derived peptide and vaccine containing same
RS65225B1 (en) Medicament for the treatment and/or prevention of endometriosis
GB201820614D0 (en) MHC Class I associated peptides for prevention and treatment of hepatitis B virus infection
EP4025585A4 (en) Modified peptides and associated methods of use
EP3615551A4 (en) Modified cyclic peptides and therapeutic use thereof
ZA201803649B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases